PT  - JOURNAL ARTICLE
ED  - ,
TI  - SSRIs for premenstrual dysphoric disorder
AID  - 10.1136/dtb.2002.40970
DP  - 2002 Sep 01
TA  - Drug and Therapeutics Bulletin
PG  - 70--72
VI  - 40
IP  - 9
4099  - http://dtb.bmj.com/content/40/9/70.short
4100  - http://dtb.bmj.com/content/40/9/70.full
SO  - Drug Ther Bull2002 Sep 01; 40
AB  - Relevant BNF section: 4.3.3Around 2-10% of women have premenstrual symptoms that severely disrupt daily living.1–3 When such symptoms are dominated by severe disturbances of mood and behaviour, the condition has been named premenstrual dysphoric disorder (PMDD).4 Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI), is licensed in the UK for the treatment of PMDD. Here, we discuss the diagnosis of PMDD and the evidence for the efficacy of fluoxetine and other SSRIs in its treatment.